Shandong Chenxin Fodu Pharmaceutical Co., Ltd.

Primary Objective: Preliminary dose-duration-effect study: This study aimed to describe the skin response at the administration site following a single topical administration of fluticasone propionate cream (Cutivate®, 0.05% (15 g)) certified by GlaxoSmithKline (Ireland) Limited to healthy study participants, obtaining three dose durations (ED50, D1, and D2) to provide a reference for a pivotal human bioequivalence study. Pivotal In Vivo Bioequivalence Study: Using fluticasone propionate cream (0.05% (15 g)) certified by Shandong Chenxin Fodu Pharmaceutical Co., Ltd. as the test formulation and fluticasone propionate cream (Cutivate®, 0.05% (15 g)) certified by GlaxoSmithKline (Ireland) Limited as the reference formulation, the pharmacodynamic parameter skin response colorimetric values at the administration site were compared after a single topical administration of the test formulation (T) or the reference formulation (R) to evaluate the human bioequivalence of the two formulations. Secondary objective: To evaluate the safety of the test formulation and the reference formulation in participants of the Chinese Adult Health Study.

Primary objective: To investigate the pharmacokinetic characteristics of fluticasone propionate cream (0.05% (15 g)) certified by Shandong Chenxin Fodu Pharmaceutical Co., Ltd., applied topically on an empty stomach; using fluticasone propionate cream (Cutivate®, 0.05% (15 g)) certified by GlaxoSmithKline (Ireland) Limited as the reference formulation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to study the difference in in vivo exposure between the test and reference formulations after topical administration. Secondary objective: To evaluate the safety of the test and reference formulations in Chinese adult healthy study participants.

Primary objective: To evaluate the effectiveness of lifalast eye drops in the treatment of patients with dry eye. Secondary objective: To evaluate the safety of lifalast eye drops.